3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
CNS
1
Conditions
Breast Neoplasms
26
Prostatic Neoplasms
15
Carcinoma, Non-Small-Cell Lung
10
Sarcoma
9
Lung Neoplasms
6
Uterine Cervical Neoplasms
5
Endometrial Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Pancreatic Neoplasms
3
Neoplasms
3
Liposarcoma, Myxoid
3
Head and Neck Neoplasms
3
Glioblastoma
3
Carcinoma, Intraductal, Noninfiltrating
3
Breast Carcinoma In Situ
3
Urogenital Neoplasms
2
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma, Synovial
2
Radiation Injuries
2
Neurofibrosarcoma
2
Neoplasm Metastasis
2
Melanoma
2
Lymphatic Metastasis
2
Liposarcoma
2
Leiomyosarcoma
2
Histiocytoma, Malignant Fibrous
2
Fibrosarcoma
2
Cholangiocarcinoma
2
Interventions
tanezumab
1
siltuximab
1
erenumab
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Saline Solution
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Protons
1
Proton Therapy
1
Mn-PyC3A
1
Lapatinib
1
Hyperspectral Imaging
1
HDAC-42
1
Bevacizumab
1
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neurilemmoma
×
Radiation Dose Hypofractionation
×
Clear all
NCT04278118
2026-02-17
HiPPI
Emory University
Phase NA
Recruiting
70 enrolled